Claims

1. A pharmaceutical composition for treatment of liver cancer, comprising:

(1) (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide represented by the following formula 1 or a pharmaceutically acceptable salt thereof; and

(2) sorafenib represented by the following formula 2 or a pharmaceutically acceptable salt thereof:

Formula 1



;

Formula 2



as active ingredients.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable salt of sorafenib is a p-toluenesulfonate salt.

3. The pharmaceutical composition of claim 1, wherein the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt thereof is administered parenterally or orally.

4. The pharmaceutical composition of claim 1, wherein the

sorafenib or the pharmaceutically acceptable salt thereof is administered orally.

5. The pharmaceutical composition of claim 1, wherein the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt is administered 1 to 5 times per week.

6. The pharmaceutical composition of claim 1, wherein the sorafenib or the pharmaceutically acceptable salt thereof is administered 1 to 7 times per week.

7. The pharmaceutical composition of claim 6, wherein the sorafenib or the pharmaceutically acceptable salt thereof is administered once or twice per day.

8. The pharmaceutical composition of claim 1, wherein the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt is administered 1 to 5 times per week, and the sorafenib or the pharmaceutically acceptable salt thereof is administered 1 to 7 times per week.

9. The pharmaceutical composition of claim 1, wherein the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt thereof is administered parenterally once per week on day 1 of each week, and the sorafenib or the pharmaceutically acceptable salt thereof is administered once per day during day 1 to day 6 of each week.

10. The pharmaceutical composition of claim 1, wherein the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt

thereof is administered orally once per day on days 1, 3 and 5 of each week (three times per week), and the sorafenib or the pharmaceutically acceptable salt thereof is administered once per day (7 times per week).

11. The pharmaceutical composition of claim 4, wherein the sorafenib or the pharmaceutically acceptable salt thereof is administered at 20 minutes to 1 hour after oral administration of the (S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide or the pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition for treatment of liver cancer, comprising:

(S)-N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide represented by the following formula 1 or a pharmaceutically acceptable salt thereof:

Formula 1



as active ingredient,

wherein the pharmaceutical composition is co-administrated with sorafenib represented by the following formula 2 or a pharmaceutically acceptable salt thereof:

Formula 2

